Armata Pharmaceuticals (ARMP) Cash from Financing Activities (2013 - 2026)

Armata Pharmaceuticals has reported Cash from Financing Activities for 13 years, with the latest figure at $641000.0 in Q1 2026.

• Quarterly Cash from Financing Activities fell 93.58% year-over-year to $641000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $16.3 million (up 62.46% YoY) and the FY2025 annual result came in at $25.6 million, down 26.73% from the prior year.
• Cash from Financing Activities retreated to $641000.0 in Q1 2026 per ARMP's latest filing, from $658000.0 in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $44.6 million in Q1 2022 and troughed at -$500000.0 in Q4 2022.
• A 5-year average of $10.6 million and a median of $641000.0 in 2026 frame the typical range for Cash from Financing Activities.
• The widest YoY moves for Cash from Financing Activities: up 79916.13% in 2023, down 152.05% in 2023.
• Over 5 years, Cash from Financing Activities stood at -$500000.0 in 2022, then soared by 91.4% to -$43000.0 in 2023, then sank by 41.86% to -$61000.0 in 2024, then surged by 1178.69% to $658000.0 in 2025, then decreased by 2.58% to $641000.0 in 2026.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered $641000.0, $658000.0, and $15.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.